Improving Heart Health in Appalachia
HeartHealth
Reducing Health Disparities in Appalachians With Multiple Cardiovascular Disease Risk Factors
1 other identifier
interventional
330
1 country
1
Brief Summary
Individuals in Appalachian Kentucky are vulnerable to cardiovascular disease (CVD) by virtue of having high rates of multiple CVD risk factors. There is a critical need to develop and test CVD risk reducing interventions that are appropriate and effective in Appalachia. In the absence of such interventions, the dramatic CVD disparities seen in this area will continue to rise. Lifestyle interventions reduce CVD risk by 44%. The investigators and others have demonstrated that lifestyle change is most effective when patients are given the tools to engage in effective self-care, and that interventions individualized to patients' specific needs and barriers are more effective than interventions that are not. The central hypothesis is that to be successful in Appalachia, CVD risk reducing interventions must focus on patient-centered lifestyle change that increase individuals' abilities to engage in self-care, must be culturally appropriate, and must have components that overcome barriers faced by individuals living in Appalachia. The investigators propose a randomized, controlled comparative effectiveness trial with 300 individuals from Appalachian Kentucky who do not have a primary care provider and who are at risk for CVD by virtue of having two or more modifiable CVD risk factors. The investigators will compare (1) a patient-centered, culturally appropriate, self-care CVD risk reduction intervention (HeartHealth) designed to improve multiple CVD risk factors while overcoming barriers to success with (2) referral of patients to a primary care provider for management of their CVD risk factors. The investigators propose the following specific aims to be tested at 4 months and 1 year after baseline. To compare the short and long-term impact of the interventions on: 1\) the risk factor selected by patients (i.e., tobacco use, blood pressure, lipid profile, hemoglobin-A1c (HgA1c) for diabetics, body mass index, waist circumference, depressive symptoms, or physical activity level); 2) all of the CVD risk factors of each patient; 3) quality of life; 4) patient and healthcare provider satisfaction; 5) desirability and adoptability by assessing adherence to recommended CVD risk reduction measures, and retention of recruited individuals. The investigators hypothesize that in comparison to the referral strategy, the multifaceted patient-centered, self-care intervention will engender more favorable outcomes across all measures.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable obesity
Started Aug 2013
Typical duration for not_applicable obesity
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 14, 2013
CompletedFirst Posted
Study publicly available on registry
June 21, 2013
CompletedStudy Start
First participant enrolled
August 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2016
CompletedMarch 10, 2017
March 1, 2017
3.4 years
June 14, 2013
March 7, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
cardiovascular risk factor selected by patient
Patient selects their own risk reduction goal from the following: smoking, blood pressure, lipid profile, body mass index, hemoglobin-A1c for diabetics, depression, physical activity level, waist circumference
4 months
cardiovascular risk factor selected by patient
Patient selects their own risk reduction goal from the following: smoking, blood pressure, lipid profile, body mass index, hemoglobin-A1c for diabetics, depression, physical activity level, waist circumference
12 months
Secondary Outcomes (2)
all CVD risk factors of each patient
4 months
all CVD risk factors of each patient
12 months
Other Outcomes (2)
quality of life
4 months
quality of life
12 months
Study Arms (2)
Self-care CVD risk reduction
EXPERIMENTALA patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.
Referral to primary care provider
ACTIVE COMPARATORThe study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.
Interventions
A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.
The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.
Eligibility Criteria
You may qualify if:
- residents of eastern Appalachian Kentucky
- do not have a primary care provider
- at risk for CVD as reflected by having two or more of the following modifiable risk factors
- clinical diagnosis of hypertension or taking medications diagnosed for hypertension or found to be hypertensive on screening;
- clinical diagnosis of hyperlipidemia or taking medication for treating abnormal lipid levels, or any lipid abnormality found on screening that indicates hyperlipidemia;
- diagnosis of type 2 diabetes or HgA1c \> 7% found on screening;
- overweight or obese (body mass index ≥ 25 kg/m2);
- waist circumference \> 40 inches in men or \> 35 inches in women;
- clinical diagnosis of depression, on medications for depression or found to have depressive symptoms (score of \> 9 on the Patient Health Questionnaire-9) by baseline screening;
- sedentary lifestyle meaning that the individual does not engage in at least 30 minutes of moderate activity for at least 4 days per week
You may not qualify if:
- known coronary artery disease, cerebrovascular disease, history of acute coronary syndrome or peripheral arterial disease;
- taking medications (e.g., protease inhibitors) that interfere with lipid metabolism;
- cognitive impairment that precludes an individual from understanding the consent process, answering questionnaires, or participating in the intervention;
- chronic drug abuse;
- end-stage renal or liver or pulmonary disease;
- current active cancer (i.e., undergoing active treatment for cancer) other than isolated skin cancer treatable by simple excision;
- gastrointestinal disease that requires special diets (e.g., Crohn's disease; celiac disease)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Kentucky
Lexington, Kentucky, 40535, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Debra K Moser, DNSc, RN
University of Kentucky
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
June 14, 2013
First Posted
June 21, 2013
Study Start
August 1, 2013
Primary Completion
December 31, 2016
Study Completion
December 31, 2016
Last Updated
March 10, 2017
Record last verified: 2017-03